PDF herunterladen
Semin Respir Crit Care Med 2005; 26(6): 635-642
DOI: 10.1055/s-2005-925527
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Antibody-Mediated Protection against Respiratory Viral Infection

Melissa E. Dubois1 , Paul Yoshihara2 , Mark K. Slifka1
  • 1Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon
  • 2Najít Technologies, Inc., Portland, Oregon
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
30. Dezember 2005 (online)

    Lizenzen und Reprints

ABSTRACT

Effective antibody responses are critical for protection against many human pathogens, including those with tropism for the respiratory tract (RT). Systemic immunoglobulin (Ig)G responses as well as mucosal IgA responses play complementary roles in protection against RT infections, and induction of a tissue-specific, isotype-appropriate humoral response is central to successful vaccination strategies. For respiratory virus infections in which current vaccines are either not available or not fully effective, antibody-mediated therapies may provide a viable treatment option. Prophylactic administration of polyclonal or monoclonal antibodies shows the best clinical efficacy, whereas therapeutic administration of antibodies after infection can also be highly protective but is greatly dependent on timing; efficacy declines soon after onset of disease symptoms. Further understanding of the mechanisms underlying antibody-mediated protection against respiratory virus infections may lead to improved immunization strategies as well as more effective antibody-based therapeutics.

KEYWORDS

Respiratory virus - antibody-mediated therapy - monoclonal antibody - vaccine - respiratory - virus - host defenses

REFERENCES

  • 1 Whitton J L, Slifka M K, Liu F et al.. The regulation and maturation of antiviral immune responses.  Adv Virus Res. 2004;  63 181-238
    PubMedGoogle Scholar
  • 2 Slifka M K, Hanifin J M. Smallpox: the basics.  Dermatol Clin. 2004;  22 263-274 vi
    PubMedGoogle Scholar
  • 3 Epstein S L, Lo C Y, Misplon J A et al.. Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice.  J Immunol. 1997;  158 1222-1230
    PubMedGoogle Scholar
  • 4 Edghill-Smith Y, Bray M, Whitehouse C A et al.. Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.  J Infect Dis. 2005;  191 372-381
    CrossrefPubMedGoogle Scholar
  • 5 Bouvet J P, Fischetti V A. Diversity of antibody-mediated immunity at the mucosal barrier.  Infect Immun. 1999;  67 2687-2691
    PubMedGoogle Scholar
  • 6 Holmgren J, Czerkinsky C. Mucosal immunity and vaccines.  Nat Med. 2005;  11(Suppl 4) S45-S53
    PubMedGoogle Scholar
  • 7 Slifka M K, Ahmed R. Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity.  Trends Microbiol. 1996;  4 394-400
    CrossrefPubMedGoogle Scholar
  • 8 Franklin E C. Structure and function of immunoglobulins.  Acta Endocrinol Suppl(Copenh). 1975;  194 77-95
    PubMedGoogle Scholar
  • 9 Stockwin L H, Holmes S. Antibodies as therapeutic agents: vive la renaissance!.  Expert Opin Biol Ther. 2003;  3 1133-1152
    CrossrefPubMedGoogle Scholar
  • 10 Burton D R. Opinion: antibodies, viruses and vaccines.  Nat Rev Immunol. 2002;  2 706-713
    CrossrefPubMedGoogle Scholar
  • 11 Griffin D, Levine B, Tyor W et al.. The role of antibody in recovery from alphavirus encephalitis.  Immunol Rev. 1997;  159 155-161
    PubMedGoogle Scholar
  • 12 Fujioka H, Emancipator S N, Aikawa M et al.. Immunocytochemical colocalization of specific immunoglobulin A with Sendai virus protein in infected polarized epithelium.  J Exp Med. 1998;  188 1223-1229
    CrossrefPubMedGoogle Scholar
  • 13 Mazanec M B, Coudret C L, Fletcher D R. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies.  J Virol. 1995;  69 1339-1343
    PubMedGoogle Scholar
  • 14 Bomsel M, Heyman M, Hocini H et al.. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein dIgA or IgM.  Immunity. 1998;  9 277-287
    CrossrefPubMedGoogle Scholar
  • 15 Kato H, Kato R, Fujihashi K, McGhee J R. Role of mucosal antibodies in viral infections.  Curr Top Microbiol Immunol. 2001;  260 201-228
    PubMedGoogle Scholar
  • 16 Schmaljohn A L, Johnson E D, Dalrymple J M, Cole G A. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis.  Nature. 1982;  297 70-72
    PubMedGoogle Scholar
  • 17 Gould E A, Buckley A, Barrett A D, Cammack N. Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice.  J Gen Virol. 1986;  67(Pt 3) 591-595
    PubMedGoogle Scholar
  • 18 Cox R J, Brokstad K A, Ogra P. Influenza virus: immunity and vaccination strategies: comparison of the immune response to inactivated and live, attenuated influenza vaccines.  Scand J Immunol. 2004;  59 1-15
    CrossrefPubMedGoogle Scholar
  • 19 Tamura S, Iwasaki T, Thompson A H et al.. Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection.  J Gen Virol. 1998;  79(Pt 2) 291-299
    PubMedGoogle Scholar
  • 20 Tamura S, Kurata T. Defense mechanisms against influenza virus infection in the respiratory tract mucosa.  Jpn J Infect Dis. 2004;  57 236-247
    PubMedGoogle Scholar
  • 21 Renegar K B, Small Jr P A, Boykins L G, Wright P F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract.  J Immunol. 2004;  173 1978-1986
    PubMedGoogle Scholar
  • 22 Fenner F, Henderson D A, Arita I et al.. Smallpox and Its Eradication: The Pathogenesis, Immunology, and Pathology of Smallpox and Vaccinia. Geneva; World Health Organization 1988
    Google Scholar
  • 23 Hammarlund E, Lewis M W, Hansen S G et al.. Duration of antiviral immunity after smallpox vaccination.  Nat Med. 2003;  9 1131-1137
    PubMedGoogle Scholar
  • 24 Crotty S, Felgner P, Davies H et al.. Cutting edge: long-term B cell memory in humans after smallpox vaccination.  J Immunol. 2003;  171 4969-4973
    PubMedGoogle Scholar
  • 25 CDC . Impact of vaccines universally recommended for children: United States, 1990-1998.  MMWR Morb Mortal Wkly Rep. 1999;  48 243-248
    PubMedGoogle Scholar
  • 26 Amanna I, Slifka M K. Public fear of vaccination: separating fact from fiction.  Viral Immunol. 2005;  18 307-315
    CrossrefPubMedGoogle Scholar
  • 27 Christie C D, Marx M L, Daniels J A, Adcock M P. Pertussis containment in schools and day care centers during the Cincinnati epidemic of 1993.  Am J Public Health. 1997;  87 460-462
    PubMedGoogle Scholar
  • 28 Kim H W, Canchola J G, Brandt C D et al.. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.  Am J Epidemiol. 1969;  89 422-434
    PubMedGoogle Scholar
  • 29 Chin J, Magoffin R L, Shearer L A et al.. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.  Am J Epidemiol. 1969;  89 449-463
    PubMedGoogle Scholar
  • 30 Fulginiti V A, Eller J J, Sieber O F et al.. Respiratory virus immunization, I: A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.  Am J Epidemiol. 1969;  89 435-448
    PubMedGoogle Scholar
  • 31 Kapikian A Z, Mitchell R H, Chanock R M et al.. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.  Am J Epidemiol. 1969;  89 405-421
    PubMedGoogle Scholar
  • 32 Chihrin S, Loutfy M R. Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome.  Expert Rev Anti Infect Ther. 2005;  3 251-262
    CrossrefPubMedGoogle Scholar
  • 33 Wesselhoeft C. Treatment of scarlet fever and diphtheria.  Med Clin North Am. 1936;  19 1389-1407
    PubMedGoogle Scholar
  • 34 Skerrett S J. Antibody treatment of lower respiratory tract infections.  Semin Respir Infect. 2001;  16 67-75
    PubMedGoogle Scholar
  • 35 Zeitlin L, Cone R A, Moench T R, Whaley K J. Preventing infectious disease with passive immunization.  Microbes Infect. 2000;  2 701-708
    CrossrefPubMedGoogle Scholar
  • 36 Casadevall A. Passive antibody therapies: progress and continuing challenges.  Clin Immunol. 1999;  93 5-15
    CrossrefPubMedGoogle Scholar
  • 37 Casadevall A. Antibody-based therapies for emerging infectious diseases.  Emerg Infect Dis. 1996;  2 200-208
    PubMedGoogle Scholar
  • 38 Casadevall A, Scharff M D. Return to the past: the case for antibody-based therapies in infectious diseases.  Clin Infect Dis. 1995;  21 150-161
    PubMedGoogle Scholar
  • 39 Sawyer L A. Antibodies for the prevention and treatment of viral diseases.  Antiviral Res. 2000;  47 57-77
    CrossrefPubMedGoogle Scholar
  • 40 Dunman P M, Nesin M. Passive immunization as prophylaxis: when and where will this work?.  Curr Opin Pharmacol. 2003;  3 486-496
    PubMedGoogle Scholar
  • 41 Liu W, Zou P, Chen Y H. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.  Immunol Lett. 2004;  93 131-136
    CrossrefPubMedGoogle Scholar
  • 42 Traggiai E, Becker S, Subbarao K et al.. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.  Nat Med. 2004;  10 871-875
    PubMedGoogle Scholar
  • 43 Maggon K, Barik S. New drugs and treatment for respiratory syncytial virus.  Rev Med Virol. 2004;  14 149-168
    CrossrefPubMedGoogle Scholar
  • 44 Hwang W Y, Foote J. Immunogenicity of engineered antibodies.  Methods. 2005;  36 3-10
    CrossrefPubMedGoogle Scholar
  • 45 Peterson N C. Advances in monoclonal antibody technology: genetic engineering of mice, cells, and immunoglobulins.  ILAR J. 2005;  46 314-319
    PubMedGoogle Scholar
  • 46 AmericanAcademyofPediatrics . Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.  Pediatrics. 2003;  112(6 Pt 1) 1442-1446
    CrossrefPubMedGoogle Scholar
  • 47 DeVincenzo J P, Hall C B, Kimberlin D W et al.. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.  J Infect Dis. 2004;  190 975-978
    CrossrefPubMedGoogle Scholar
  • 48 Zhao X, Chen F P, Sullender W M. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.  Virology. 2004;  318 608-612
    CrossrefPubMedGoogle Scholar
  • 49 Zhao X, Chen F P, Megaw A G, Sullender W M. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.  J Infect Dis. 2004;  190 1941-1946
    CrossrefPubMedGoogle Scholar
  • 50 Yang Z Y, Werner H C, Kong W P et al.. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses.  Proc Natl Acad Sci U S A. 2005;  102 797-801
    CrossrefPubMedGoogle Scholar
  • 51 Lang A B, Cryz Jr S J, Schurch U et al.. Immunotherapy with human monoclonal antibodies: fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin.  J Immunol. 1993;  151 466-472
    PubMedGoogle Scholar
  • 52 Cheng Y, Wong R, Soo Y O et al.. Use of convalescent plasma therapy in SARS patients in Hong Kong.  Eur J Clin Microbiol Infect Dis. 2005;  24 44-46
    Google Scholar
  • 53 Keller M A, Stiehm E R. Passive immunity in prevention and treatment of infectious diseases.  Clin Microbiol Rev. 2000;  13 602-614
    CrossrefPubMedGoogle Scholar
  • 54 Harrison L H, Halsey N A, McKee Jr K T et al.. Clinical case definitions for Argentine hemorrhagic fever.  Clin Infect Dis. 1999;  28 1091-1094
    PubMedGoogle Scholar
  • 55 Enria D A, Barrera Oro J G. Junin virus vaccines.  Curr Top Microbiol Immunol. 2002;  263 239-261
    PubMedGoogle Scholar
  • 56 Patel T B, Naidu B PB. Smallpox and sulphonamide.  Indian Med Gaz. 1940;  75 730-732
    PubMedGoogle Scholar
  • 57 Couzi G, Kircher J P. Immunotherapie de la Variole.  Bulletin de l'Institut d'hygiene du Maroc. 1941;  1 59-68
    PubMedGoogle Scholar

Mark K SlifkaPh.D. 

Vaccine and Gene Therapy Institute, Oregon Health and Science University, 505 NW 185th Ave., Beaverton, OR 97006

eMail: slifkam@ohsu.edu

      >